H.I.G. Capital sells Celerion Holdings to THL Partners
The platform investment centers on a clinical pharmacology-focused contract research organization, to THL Partners for $1, with transaction terms undisclosed in the announcement.
H.I.G. Capital sold Celerion Holdings Inc, a clinical pharmacology-focused contract research organization, to THL Partners for $1.8 billion.
Celerion provides early clinical trial solutions, including first-in-human to proof-of-concept studies and bioanalytical laboratory services, to pharmaceutical and biotechnology companies across North America, Europe, and Asia.
The sale is the latest exit from H.I.G.'s Advantage strategy, following the sales of St. Croix and United Flow Technologies since late 2025.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.